Media Articles Related to Anturane (Sulfinpyrazone)
UK rates of gout soaring, but treatment remains poor
Source: Gout News From Medical News Today [2014.01.16]
UK rates of gout have soared since the late1990s, with one in every 40 people now affected by the condition - the highest in Europe - but treatment remains as poor now as it was then, reveals research published online in the Annals of the Rheumatic Diseases.
Gout runs strongly in families, suggests large-scale study
Source: Gout News From Medical News Today [2013.12.03]
Researchers from the UK's University of Nottingham and colleagues conducted a new study of the population of Taiwan, where there is a high rate of gout, and found that the condition clusters in families.
Gout (Gouty Arthritis)
Source: MedicineNet Bunions Specialty [2013.12.03]
Title: Gout (Gouty Arthritis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/3/2013 7:21:42 PM
Less than half of gout patients reach recommended treatment goal following treatment with allopurinol
Source: Gout News From Medical News Today [2013.10.31]
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout.
Risk of heart attack and stroke doubles for patients with gout
Source: Gout News From Medical News Today [2013.10.03]
New research published in Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.The findings showed that gout patients are twice as likely to suffer a heart attack or stroke as those without gout.
Published Studies Related to Anturane (Sulfinpyrazone)
The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. 
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.
Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...
Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.